Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or Microbicides
Open Access
- 1 August 2010
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 285 (33), 25506-25515
- https://doi.org/10.1074/jbc.m110.101170
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion InhibitorsJournal of Biological Chemistry, 2009
- Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsProceedings of the National Academy of Sciences of the United States of America, 2008
- Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249Proceedings of the National Academy of Sciences of the United States of America, 2008
- N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virusVirology, 2007
- Potent D-peptide inhibitors of HIV-1 entryProceedings of the National Academy of Sciences, 2007
- Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusProceedings of the National Academy of Sciences, 2007
- The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formationBiochemical Journal, 2007
- Microbicides: stopping HIV at the gateThe Lancet, 2006
- Cellulose Acetate 1,2-Benzenedicarboxylate Inhibits Infection by Cell-Free and Cell-Associated Primary HIV-1 IsolatesAIDS Research and Human Retroviruses, 2006
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994